SRP-1003 Shows Nuclear DMPK RNA Knockdown

Company Sarepta Therapeutics Event Type Preclinical Data Presentation (Oligonucleotide Therapeutics Society) Modality siRNA; alpha-v-beta-6 integrin-targeted muscle delivery Asset SRP-1003 Target DMPK RNA (nuclear and cytoplasmic) Disease Area Myotonic dystrophy type 1 (DM1) Summary Sarepta presented new preclinical data showing that its alpha-v-beta-6 integrin-targeted siRNA SRP-1003…